What is Amarin's gross profit margin?

What guidance did Amarin's management provide for the next earnings period?

What were the key takeaways from Amarin’s earnings call?

Did Amarin beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Amarin next quarter?

What is Amarin's latest dividend and current dividend yield?

What does Amarin do and what are its main business segments?

What were the key takeaways from Amarin's earnings call?

- **U.S. Market Dominance**: >50% IPE share sustained with 34% YoY revenue growth, driven by pricing and exclusive PBM regain.
- **Partnership Payoff**: Europe transition on track, with $70M OpEx savings flowing through to -22% operating margin (vs. -60% prior year).
- **FDA Label Win**: Fenofibrate's cardiovascular benefit removed, creating tailwind for VASCEPA in fibrate-heavy markets.
- **2026 Outlook**: Free cash flow target achievable via reduced OpEx offsetting gross margin decline from partner model.

**【CEO Summary Section】**
- **Strategic Partnerships**: Announced a fully partnered commercial model with Recordati in Europe, transitioning to 7 global partners covering 100 markets. Europe transition is on track for full handover by end-2025, with demand growth across all launch geographies.
- **Cost Efficiency**: Achieved $70 million OpEx savings through restructuring, with $17.2 million paid as of Q3. Operating loss reduced 56% YoY to $11.1 million, improving margin to -22% (vs. -60% prior year).
- **U.S. Market Resilience**: Maintained >50% share of IPE market, regaining exclusive status with a large PBM, driving $10.3 million U.S. revenue growth (34% YoY). Net selling price increased due to customer mix shift.
- **Scientific Validation**: VASCEPA included in 2025 ESC/EAS guidelines as Class IIa for high-risk patients, supported by REDUCE-IT data. FDA updated fenofibrate labeling to reflect lack of cardiovascular benefit, aligning with VASCEPA's proven outcomes.

**【CFO Financial Commentary】**
- **Revenue Performance**: Q3 2025 total revenue $49.7 million (+17% YoY), driven by U.S. sales ($40.9 million, +34% YoY). Europe product revenue $4.1 million (flat YoY), reflecting transition to partner model. Rest of World revenue $3.6 million (-50% YoY) due to launch timing variability.
- **Expense Management**: SG&A reduced 47% YoY to $19.7 million. R&D $4.2 million, supporting global regulatory efforts. Restructuring costs $9.4 million (total $32.2 million to date), with $17.2 million paid.
- **Cash Position**: $286.6 million in cash, no debt, supporting 2026 free cash flow target.

**【Q&A Key Highlights】**
- **U.S. Pricing Outlook**: Net price expected stable for remainder of 2025, with 2026 rebate negotiations ongoing. Historical trend shows 10%+ decline in early 2026 based on contracts.
- **Recordati Milestones**: Triggered at $100 million+ sales, with payments tied to sales growth. Europe sales momentum expected to accelerate post-transition.
- **Gross Margin Trajectory**: U.S. sales (higher margin) will decline as partner model (lower margin) scales. Operating margin improvement will offset gross margin contraction via reduced OpEx.
- **Fenofibrate Impact**: FDA label change may shift prescribing to VASCEPA, particularly in markets with high fibrate use. Europe and Rest of World partners may benefit from reduced competition.
- **Rest of World Volatility**: Supply shipments to partners vary by launch timing, with Q3 2025 Rest of World revenue down 50% YoY due to lack of new launches.

Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript

- **Europe Partnership Success**: Recordati transition to drive 17% QoQ demand growth, with Italy at 91% reimbursement coverage.
- **$70M Cost Savings**: Global restructuring to reduce expenses, supporting partner growth.
- **ROW Outperformance**: China (+68% QoQ), Australia (+75% QoQ), and Middle East (+62% QoQ) lead ROW revenue surge.
- **U.S. Resilience**: 43% market share maintained despite generics; July 2025 share rebound to 50% post-payer exclusivity.
- **Financial Strength**: $298.7M cash, no debt, with accelerating path to positive cash flow.

**【CEO Summary Section】**
- **Strategic Partnership with Recordati**: Entered a long-term licensing agreement for VAZKEPA in Europe, aiming to accelerate commercialization and leverage Recordati's cardiovascular expertise. Transition to full commercial control by end-2025.
- **Cost Savings Initiative**: Global restructuring to achieve $70 million in operating expense savings over 12 months, enhancing efficiency and focus on partner support.
- **Global Growth Momentum**: 
  - Europe: End-market demand up 17% QoQ (132% YoY), driven by Spain, UK, and Italy (91% reimbursement coverage). 
  - Rest of World (ROW): ROW revenue +3.5M (vs. 0.1M YoY), with China (+68% QoQ), Australia (+75% QoQ), and Middle East (+62% QoQ) leading growth.
- **U.S. Resilience**: Maintained 43% market share despite 17% YoY revenue decline, with July 2025 market share rebounding to ~50% post-payer exclusivity reinstatement.

**【CFO Financial Commentary】**
- **Q2 2025 Financials**: 
  - Total net revenue: $72.7M (+8% YoY), driven by Recordati upfront payment.
  - Product revenue: $46.6M (-2% YoY), with U.S. decline offset by Europe (+100% YoY) and ROW (+14x YoY).
  - Licensing/royalty revenue: $26.1M (+31% YoY), reflecting partner growth.
- **Expense Management**: 
  - SG&A/R&D: $38.7M (flat YoY), with restructuring savings to begin Q3.
  - COGS: $22.4M (-9% YoY), benefiting from scale.
- **Balance Sheet Strength**: $298.7M cash, 0 debt, sufficient inventory for global demand.

**【Q&A Highlights】**
- **U.S. Strategy**: 
  - No AG launch planned; prioritize branded VASCEPA to maintain 40%+ IPE share.
  - 2026 formulary outlook uncertain; focus on exclusive account retention.
- **Europe Transition**: 
  - Recordati's primary care + cardiology reach expected to accelerate penetration beyond specialists.
  - Italy launch progress: 91% regional reimbursement secured.
- **Cost Savings Timeline**: 
  - $70M savings straight-lined over 4Q; Q3/Q4 savings gradual due to transition costs.
- **Strategic Options**: 
  - Exploring all value-creation opportunities (M&A, partnerships) with Barclays as advisor; no timeline defined.

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

- **Europe Outperforming**: Q1 2025 European revenue up 16% sequentially, with Italy targeting 85% market access and Austria/Norway securing reimbursement.
- **U.S. Resilience**: Maintained $35.7 million in Q1 revenue despite generics, with strategic authorized generic launch planning.
- **Global Expansion**: 21 countries now reimburse VASCEPA, including 9 RoW markets with early commercial success in Australia and China.
- **Financial Strength**: $282 million cash with no debt, operating expenses down 8% YoY, and gross margin improving to 59%.
- **Scientific Leadership**: Over 50 global guideline inclusions and active REDUCE-IT data mining to differentiate against generics.


**【CEO Summary Section】**
- **Europe Growth Momentum**: Q1 2025 European revenue reached $5.4 million, up 16% sequentially, driven by Spain, UK, and CEE markets. Italy secured access in 14/21 regions (85% of eligible market), setting stage for 2025 launch acceleration. Austria and Norway achieved reimbursement, with decisions expected in 2025.
- **U.S. Stability**: Maintained profitability with $35.7 million in Q1 revenue, despite generic competition. Retained all major accounts, signaling strong commercial execution. Authorized generic launch timing remains strategic.
- **Global Expansion**: 21 countries now have VASCEPA reimbursement (vs. 7 in 2023), with 9 RoW markets commercialized. China partner EddingPharm focuses on high-risk self-pay patients ahead of 2026 NRDL inclusion. Australia saw strong demand post-inclusion in clinical guidelines.
- **R&D & Medical Affairs**: 100+ abstracts and 150+ educational initiatives since 2023, reinforcing VASCEPA's CV risk reduction profile. Global guideline inclusion now exceeds 50.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: Total revenue $42 million (-25% YoY), driven by U.S. generic competition (U.S. product revenue $35.7 million vs. $48.1 million YoY). European gross margin improved to 59% (vs. 55% YoY) due to customer mix.
- **Cost Management**: Operating expenses reduced 8% YoY to $41.9 million, with cash burn below 10% of Q1 2025 cash balance ($282 million). No debt, supply chain optimized to avoid tariff impacts.
- **Rest of World (RoW)**: Minimal direct revenue ($<0.1 million), but partners report sequential demand growth. Launch timing variability expected as partners shift to commercialization.

**【Q&A Highlights】**
- **RoW Revenue Volatility**: Early-stage launches cause quarter-to-quarter variability, but in-market demand trends positive. Partnerships with strong commercial presence (e.g., CSL Seqirus in Australia) drive optimism.
- **Scientific Differentiation**: Ongoing REDUCE-IT data mining highlights IPE's residual risk reduction beyond LDL-C. Global guideline inclusion (50+) and clinical trial participation (e.g., ACC presentations on anti-inflammatory mechanisms) reinforce VASCEPA's unique value proposition.
- **Generic Landscape**: Focus on maximizing authorized generic timing to extend U.S. franchise life. Global patent portfolio (e.g., Europe to 2039) provides runway for differentiation against generics.


Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

- **Global Expansion Momentum**: 49 market approvals, 20+ launched markets, $294M cash runway
- **US Resilience**: 74% of branded business in exclusives, $44.2M Q4 revenue despite generics
- **Europe Growth**: Spain/UK driving +63% YoY, Italy secures 50% market access
- **Strategic Action**: ADS ratio change preserves NASDAQ listing
- **Science-Driven Differentiation**: 25% CV event reduction vs. statins alone, targeting high Lp(a) patients

**【CEO Business Update】**
- 2024 total revenue: $228.6M (cash position: $294M, no debt)
- Global VASCEPA expansion: 49 market approvals, 20+ launched markets
- ADS ratio change: 1 ADS → 20 ordinary shares to maintain NASDAQ listing
- US exclusives cover 43M lives (74% of branded business)
- Europe: Spain, UK driving growth; Italy secures 50% market access
- Rest-of-world: China (generic risk reduction), Australia (PBS listing), MENA expansion

**【CFO Financial Results】**
- Q4 2024 net revenue: $62.3M (down 16% YoY)
- US product revenue: $44.2M (-32% YoY) due to generic competition
- Europe: $4M (+63% YoY) from Spain/UK
- Rest-of-world: $11.9M (+233% YoY) via partnerships
- Operating expenses: $43M (-26% YoY)
- Cash runway: stable since 2022 ($294M as of Dec 2024)

**【R&D & Global Strategy】**
- 500+ scientific publications supporting VASCEPA's cardiovascular benefits
- 15+ global approvals for cardiovascular risk reduction
- REDUCE-IT data shows 25% CV event reduction vs. statins alone
- Targeting high Lp(a) patients (20% global prevalence) with complementary therapy
- 2025 priorities: Europe expansion, US profitability, R&D investment

**【Q&A Highlights】**
- US net price variability: mix of high/low rebate business
- Cash allocation: VASCEPA global growth > pipeline diversification
- Rest-of-world growth: China (generic risk reduction), Australia (PBS listing), MENA partnerships

AMRN

AMRN fundamentals

Earnings Call

You can ask Aime